DCGI Okays Bharat Biotech, Serum Institute Vaccine Candidates for Emergency Use
The DCGI V.G. Somani announced in a press conference that the Central Drugs Standards Control Organisation has accepted the Subject Expert Committee s recommendation to approve the two vaccines.
Dr V.G. Somani addressing the press on January 3, 2021. Source: PIB/YouTube
New Delhi: India’s drug regulator announced on Sunday that the COVID-19 vaccine candidates of Serum Institute of India (SII) and Bharat Biotech have been cleared for “restricted use in an emergency situation”. The regulator’s important announcement comes a day after the subject expert committee (SEC) of the Central Drugs Standards Control Organisation recommended that the two companies’ pitches be approved.
Read more about Post expert committee recommendation, DCGI to brief media today on vaccine on Business Standard. As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of the accelerated approval process request of the SII
By Krishna N. Das NEW DELHI (Reuters) - India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the st.
Every Indian proud : PM Modi lauds emergency approval of SII and Bharat Biotech s Covid vaccines
Prime Minister Narendra Modi further added that, every Indian would be proud of the fact that two India made vaccines have been given emergency use approval.
Share Via Email
| A+A A- By Online Desk
Soon after Drugs Controller General of India (DCGI) approved Serum Institute of India (SII) and Bharat Biotecth s COVID-19 vaccine for emergency use, Prime Minister Narendra Modi took to Twitter to call the development a decisive turning point to strengthen a spirited fight , against coronavirus.
PM Modi, in a tweet, said DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators.